Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, sho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuezhi Cao, Yong Liang, Zhenxiang Hu, Huiyu Li, Jiaming Yang, Eric J. Hsu, Jiankun Zhu, Jin Zhou, Yang-Xin Fu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/8b56982268c24d6785de4d9f98953a35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b56982268c24d6785de4d9f98953a35
record_format	dspace
spelling	oai:doaj.org-article:8b56982268c24d6785de4d9f98953a352021-12-02T18:07:53ZNext generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance10.1038/s41467-021-26112-22041-1723https://doaj.org/article/8b56982268c24d6785de4d9f98953a352021-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26112-2https://doaj.org/toc/2041-1723Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, showing preserved anti-tumor activity but reduced toxicity.Xuezhi CaoYong LiangZhenxiang HuHuiyu LiJiaming YangEric J. HsuJiankun ZhuJin ZhouYang-Xin FuNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Xuezhi Cao Yong Liang Zhenxiang Hu Huiyu Li Jiaming Yang Eric J. Hsu Jiankun Zhu Jin Zhou Yang-Xin Fu Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
description	Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, showing preserved anti-tumor activity but reduced toxicity.
format	article
author	Xuezhi Cao Yong Liang Zhenxiang Hu Huiyu Li Jiaming Yang Eric J. Hsu Jiankun Zhu Jin Zhou Yang-Xin Fu
author_facet	Xuezhi Cao Yong Liang Zhenxiang Hu Huiyu Li Jiaming Yang Eric J. Hsu Jiankun Zhu Jin Zhou Yang-Xin Fu
author_sort	Xuezhi Cao
title	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
title_short	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
title_full	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
title_fullStr	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
title_full_unstemmed	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
title_sort	next generation of tumor-activating type i ifn enhances anti-tumor immune responses to overcome therapy resistance
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8b56982268c24d6785de4d9f98953a35
work_keys_str_mv	AT xuezhicao nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT yongliang nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT zhenxianghu nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT huiyuli nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT jiamingyang nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT ericjhsu nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT jiankunzhu nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT jinzhou nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance AT yangxinfu nextgenerationoftumoractivatingtypeiifnenhancesantitumorimmuneresponsestoovercometherapyresistance
_version_	1718378641781424128

Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Ejemplares similares